Amarin (AMRN) Vascepa NCE Not in Latest FDA Orange Book Update
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Up)Join SI Premium – FREE
Amarin's (Nasdaq: AMRN) Vascepa NCE is not in the latest U.S. FDA Orange Book update. To visit the FDA page, click here.
Shares are down 0.4 percent Friday.
Shares are down 0.4 percent Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
- Kiromic BioPharma (KRBP) Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Trial First Three Patients
- Ascendis Pharma (ASND) Announces UK Approval of YORVIPATH
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
